摘要
随着社会人口老龄化,我国骨质疏松症患病率急剧攀升。有效防控骨质疏松症,减少骨质疏松性骨折发生率,对于减轻疾病对国民健康和社会经济的危害具有重要意义。目前骨质疏松症治疗药物主要包括骨吸收抑制剂、骨形成促进剂和双重作用药物,上述药物长程序贯治疗能够持续增加骨密度、降低骨折风险,是骨质疏松症药物治疗的必然趋势,但基于骨折风险的科学序贯治疗方案仍需深入探索。
With the aging of the population,the prevalence of osteoporosis has rapidly risen in China.Effective prevention and treatment of osteoporosis to decrease the incidence of bone fractures are of great significance.At present,the drugs for treatment of osteoporosis mainly include antiresorptic,anabolic and dual acting agents.The long-term sequential treatment can continuously increase bone mineral density and reduce the bone fracture risk,which is the inevitable trend of treatment of osteoporosis.However,the appropriate sequential treatment protocol based on fracture risk still needs to be further explored.
作者
李梅
章振林
夏维波
LI Mei;ZHANG Zhen-lin;XIA Wei-bo(Department of Endocrinology,Key Laboratory of Endocrinology of National Health Commission,Peking Union Medical College Hospital,Chinese Academy of Medical Science&Peking Union Medical College,Beijing 100730,China;Department of Osteoporosis and Bone Disease,Shanghai Jiao Tong University Affiliated Sixth People’s Hospital,Shanghai 200233,China)
出处
《中华骨质疏松和骨矿盐疾病杂志》
CSCD
北大核心
2021年第5期441-446,共6页
Chinese Journal Of Osteoporosis And Bone Mineral Research
基金
国家自然科学基金面上项目(81873668,82070908)
北京市自然科学基金(7202153)
国家重点研发计划(2018YFA0800801)。
关键词
骨质疏松症
骨吸收抑制剂
骨形成促进剂
序贯治疗
osteoporosis
bone resorption inhibitor
bone formation promoter
sequential treatment
